tbuckley/cabot-search huggingface dataset:
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
Authors: Alessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, Stefano Luminari, Alessandra Dondi, Federica Cavallo, Francesco Merli, Anna Marina Liberati, Natalia Cenfra, Daniela Renzi, Manuela Zanni, Carola Boccomini, Andrés J M Ferreri, Sara Rattotti, Vittorio Ruggero Zilioli, Silvia Anna Bolis, Patrizia Bernuzzi, Gerardo Musuraca, Gianluca Gaidano, Tommasina Perrone, Caterina Stelitano, Alessandra Tucci, Paolo Corradini, Sara Bigliardi, Francesca Re, Emanuele Cencini, Clara Mannarella, Donato Mannina, Melania Celli, Monica Tani, Giorgia Annechini, Giovanni Manfredi Assanto, Lavinia Grapulin, Anna Guarini, Marzia Cavalli, Lucia Anna De Novi, Riccardo Bomben, Elena Ciabatti, Elisa Genuardi, Daniela Drandi, Irene Della Starza, Luca Arcaini, Umberto Ricardi, Valter Gattei, Sara Galimberti, Marco Ladetto, Robin Foà, Ilaria Del Giudice
Journal: The Lancet Haematology (2024)
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Authors: Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Suzanne M Cole, Charles G Drake, Sabina Signoretti, Mahmut Akgul, Nicholas Baniak, Elsa Li-Ning, Matthew B Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Kaimakliotis, Yasser Ged, Phillip M Pierorazio, E Jason Abel, Mehmet A Bilen, Kenneth Ogan, Helen H Moon, Krishna A Ramaswamy, Eric A Singer, Tina M Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E Delacroix, Mark J Waples, Andrew C James, Peng Wang, Toni Choueiri, M Dror Michaelson, Anil Kapoor, Daniel Y Heng, Brian Shuch, Bradley C Leibovich, Primo N Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert Uzzo, Gennady Bratslavsky, Naomi B Haas, Michael A Carducci
Journal: The Lancet Oncology (2024)
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy
Authors: Elizabeth S. Duke, Diana Bradford, Arup K. Sinha, Pallavi S. Mishra-Kalyani, Catherine C. Lerro, Donna Rivera, Emily Wearne, Claudia P. Miller, John Leighton, Hairat Sabit, Hong Zhao, Ashley Lane, Barbara Scepura, Richard Pazdur, Harpreet Singh, Paul G. Kluetz, Martha Donoghue, Nicole Drezner
Journal: Journal of Clinical Oncology (2024)

On December 13, 2023, the US Food and Drug Administration (FDA) approved eflornithine (IWILFIN, US WorldMeds) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. The approval was based on an externally controlled trial (ECT) consisting of a single-arm trial, study 3(b), compared with an external control (EC) derived from a National Cancer Institute/Children's Oncology Group-sponsored clinical trial (Study ANBL0032) and supported by confirmatory evidence. In the protocol-specified primary analysis, the event-free survival hazard ratio (HR) was 0.48 (95% CI, 0.27 to 0.85) and overall survival HR was 0.32 (95% CI, 0.15 to 0.70). The most common adverse reactions (≥5%) were hearing loss, otitis media, pyrexia, pneumonia, and diarrhea. Notably, this is the first oncology drug approval which relies on an ECT as the primary clinical data to support substantial evidence of effectiveness. This was made possible by a distinctly high-quality, comparable EC data set with consistent treatment effect estimations demonstrated in multiple sensitivity and supportive analyses. Eflornithine's manageable safety profile and strong nonclinical and mechanistic data provided further support for the approval, and the evidentiary package was evaluated in the context of high unmet need in a rare, life-threatening cancer.
Duress and Distress Versus a Neurocognitive Mess: The Challenges of Procedural Sedation in Pediatric B-ALL
Authors: Lucie M. Turcotte, Joseph P. Neglia
Journal: Journal of Clinical Oncology (2024)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration–Approved Anticancer Drugs: A Call for Systematic Data Availability
Authors: Natansh D. Modi, Sandra M. Swain, Marc Buyse, Nicole M. Kuderer, Andrew Rowland, Frank W. Rockhold, Michael J. Sorich, Ashley M. Hopkins
Journal: Journal of Clinical Oncology (2024)

Unlocking the full potential of clinical trials through comprehensive CSR and IPD sharing can revolutionize cancer care, enhance safety evaluations, and reduce bias in systematic reviews. It is time for all stakeholders to embrace transparency and advance patient-centered outcomes.
Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer
Authors: Julie A. Schmidt, Kirsten M. Woolpert, Cathrine F. Hjorth, Dóra K. Farkas, Bent Ejlertsen, Deirdre Cronin-Fenton
Journal: Journal of Clinical Oncology (2024)

PURPOSE Social characteristics, including cohabitation/marital status and socioeconomic position (SEP)—education level, employment status, and income—influence breast cancer prognosis. We investigated the impact of these social characteristics on adherence to adjuvant endocrine therapy (AET) from treatment initiation to 5 years after diagnosis. METHODS We assembled a nationwide, population-based cohort of premenopausal women diagnosed in Denmark with stage I-III, estrogen receptor–positive breast cancer during 2002-2011. We ascertained prediagnostic social characteristics from national registries. AET adherence was based on information from the Danish Breast Cancer Group and operationalized as (1) adherence trajectories (from group-based trajectory modeling) and (2) early discontinuation. We computed odds ratios (ORs) and associated 95% CI to estimate the association of cohabitation and SEP with AET adherence using multinomial and logistic regression models adjusted according to directed acyclic graphs. RESULTS Among 4,353 patients, we identified three adherence trajectories—high adherence (57%), slow decline (36%), and rapid decline (6.9%). Compared with cohabiting women, those living alone had higher ORs of slow (1.26 [95% CI, 1.08 to 1.46]) or rapid decline (1.66 [95% CI, 1.27 to 2.18]) versus high adherence. The corresponding ORs for women not working versus employed women were 1.22 (95% CI, 1.02 to 1.45) and 1.76 (95% CI, 1.30 to 2.38). For early discontinuation (17%), the ORs were 1.48 (95% CI, 1.23 to 1.78) for living alone and 1.44 (95% CI, 1.17 to 1.78) for women not working. CONCLUSION Adherence to AET was lower among women living alone or unemployed than cohabiting or employed women, respectively. These women may benefit from support programs to enhance AET adherence.
Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia
Authors: Pierre Walczak, Sofiane Fodil, Nicolas Vignal, Aurélie Cabannes-Hamy, Nicolas Boissel, Emmanuel Raffoux, Jean-Michel Cayuela, Lauriane Goldwirt, Etienne Lengliné
Journal: Blood (2024)
ATM germline pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
Authors: Sarah Elitzur, Ruth Shiloh, Jan L. C. Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Thomas Lehrnbecher, Sarah K. Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla Pozza, Stephane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, A. Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Veronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt
Journal: Blood (2024)
A scoping review assessing the usability of digital health technologies targeting people with multiple sclerosis
Authors: Fiona Tea, Adam M. R. Groh, Colleen Lacey, Afolasade Fakolade
Journal: npj Digital Medicine (2024)

Abstract Digital health technologies (DHTs) have become progressively more integrated into the healthcare of people with multiple sclerosis (MS). To ensure that DHTs meet end-users’ needs, it is essential to assess their usability. The objective of this study was to determine how DHTs targeting people with MS incorporate usability characteristics into their design and/or evaluation. We conducted a scoping review of DHT studies in MS published from 2010 to the present using PubMed, Web of Science, OVID Medline, CINAHL, Embase, and medRxiv. Covidence was used to facilitate the review. We included articles that focused on people with MS and/or their caregivers, studied DHTs (including mhealth, telehealth, and wearables), and employed quantitative, qualitative, or mixed methods designs. Thirty-two studies that assessed usability were included, which represents a minority of studies (26%) that assessed DHTs in MS. The most common DHT was mobile applications ( n = 23, 70%). Overall, studies were highly heterogeneous with respect to what usability principles were considered and how usability was assessed. These findings suggest that there is a major gap in the application of standardized usability assessments to DHTs in MS. Improvements in the standardization of usability assessments will have implications for the future of digital health care for people with MS.
All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort study
Authors: Christian Kraef, Erich Tusch, Sabine Singh, Lars Østergaard, Gerd Fätkenheuer, Antonella Castagna, Santiago Moreno, Katharina Kusejko, Bartosz Szetela, Anastasiia Kuznetsova, Janez Tomažič, Jovan Ranin, Robert Zangerle, Fredrik Mansson, Giulia Marchetti, Stéphane De Wit, Amanda Clarke, Jan Gerstoft, Daria Podlekareva, Lars Peters, Joanne Reekie, Ole Kirk
Journal: The Lancet Regional Health - Europe (2024)

All-cause and AIDS-mortality in Europe has been decreasing between 1996 and 2020. However, regional differences as well as their drivers remain unclear. This study investigates mortality differences and their drivers, including usage of and response to antiretroviral therapy (ART) and active tuberculosis (TB), among people with HIV across Europe.
The Association Between Depressive Symptoms, Access to Diabetes Care, and Glycemic Control in Five Middle-Income Countries
Authors: Lena Merkel, Felix Teufel, Deborah Carvalho Malta, Michaela Theilmann, Maja-Emilia Marcus, David Flood, Pascal Geldsetzer, Jennifer Manne-Goehler, Frank Petrak, Sebastian Vollmer, Justine Davies
Journal: Diabetes Care (2024)

The relationship between depression, diabetes, and access to diabetes care is established in high-income countries (HICs) but not in middle-income countries (MICs), where contexts and health systems differ and may impact this relationship. In this study, we investigate access to diabetes care for individuals with and without depressive symptoms in MICs.
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes
Authors: Phyo Than Htoo, Mehdi NajafZadeh, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Robert J. Glynn, Niklas Schmedt, Anouk Déruaz-Luyet, Lisette Koeneman, Julie M. Paik, Elisabetta Patorno
Journal: Diabetes Care (2024)

We compared health care resource utilization (HCRU) and costs for inpatient and outpatient services and dispensed medications in older adults with type 2 diabetes initiating empagliflozin versus dipeptidyl peptidase 4 inhibitors (DPP-4is).
Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection
Authors: Michael Rooney, Shivalee N. Duduskar, Mohamed Ghait, Johanna Reißing, Sven Stengel, Philipp A. Reuken, Stefanie Quickert, Alexander Zipprich, Michael Bauer, Ashley J. Russo, Vijay A. Rathinam, Andreas Stallmach, Ignacio Rubio, Tony Bruns
Journal: Journal of Hepatology (2024)

Background & aimsGut bacterial translocation contributes to immune dysfunction and spontaneous bacterial peritonitis (SBP) in cirrhosis. We hypothesized that exposure of peritoneal macrophages (PMs) to bacterial DNA results in type-I interferon (IFN) production, shaping subsequent immune responses, inflammasome activation, and the release of damage-associated molecular patterns (DAMPs).MethodsPMs from patients with cirrhosis were stimulated with E. coli single-stranded DNA (ssDNA), lipopolysaccharide LPS, and IFN or infected with E. coli, S. aureus, and Group B streptococcus in vitro. Cytokine release, inflammasome activation, and DAMP release were quantified by quantitative-PCR, ELISA, western blots, and reporter cells employing primary PMs, monocytes, and caspase-deficient THP-1 macrophages. Serum progranulin concentration was correlated with transplant-free survival in 77 patients with SBP.ResultsE. coli ssDNA induced strong type-I IFN activity in PMs and monocytes, priming them for enhanced LPS-mediated tumor necrosis factor production without toll-like receptor 4 tolerance induction. During in vitro macrophage bacterial infection, type-I IFN release aligned with upregulated expression of IFN-regulatory factors (IRF)1/2 and guanylate binding proteins (GBP)2/5. PMs upregulated inflammasome-associated proteins and type-I IFN upon E. coli ssDNA exposure and released interleukin-1β upon bacterial infection. Proteomic screen in mouse macrophages revealed progranulin as being caspase-11-dependent during E. coli infection. PMs and THP-1 macrophages released significant amounts of progranulin when infected with S. aureus or E. coli via gasdermin-D in a type-I IFN and caspase-5-dependent manner. During SBP, PMs upregulated IRF1, GBP2/5 and caspase-5 and higher serum progranulin concentrations were indicative of lower 90-day transplant-free survival after SBP.ConclusionsType-I IFN shapes peritoneal immune responses and regulates caspase-5-mediated progranulin release during SBP.Impact and ImplicationsPatients with cirrhosis exhibit impaired immune responses and increased susceptibility to bacterial infections. This study reveals that type-I interferon responses, triggered by pathogen-associated molecular patterns, are crucial in regulating macrophage activation and priming them for inflammatory responses. Additionally, we elucidate the mechanisms by which type-I interferons promote the release of progranulin from macrophages during spontaneous bacterial peritonitis. Our findings enhance understanding of how bacterial translocation affects immune responses, identify novel biomarkers for inflammasome activation during infections, and point to potential therapeutic targets.
Liver bioprinting within a novel support medium with functionalized spheroids, hepatic vein structures, and enhanced post-transplantation vascularization
Authors: Zhuoran Jiang, Bao Jin, Zhu Liang, Yinhan Wang, Shuai Ren, Yongfa Huang, Changcan Li, Hang Sun, Yunzhu Li, Li Liu, Nianlin Li, Jinzhuo Wang, Zhanfeng Cui, Pengyu Huang, Huayu Yang, Yilei Mao, Hua Ye
Journal: Biomaterials (2024)

Cell-laden bioprinting is a promising biofabrication strategy for regenerating bioactive transplants to address organ donor shortages. However, there has been little success in reproducing transplantable artificial organs with multiple distinctive cell types and physiologically relevant architecture. In this study, an omnidirectional printing embedded network (OPEN) is presented as a support medium for embedded 3D printing. The medium is state-of-the-art due to its one-step preparation, fast removal, and versatile ink compatibility. To test the feasibility of OPEN, exceptional primary mouse hepatocytes (PMHs) and endothelial cell line-C166, were used to print hepatospheroid-encapsulated-artificial livers (HEALs) with vein structures following predesigned anatomy-based printing paths in OPEN. PMHs self-organized into hepatocyte spheroids within the ink matrix, whereas the entire cross-linked structure remained intact for a minimum of ten days of cultivation. Cultivated HEALs maintained mature hepatic functions and marker gene expression at a higher level than conventional 2D and 3D conditions in vitro. HEALs with C166-laden vein structures promoted endogenous neovascularization in vivo compared with hepatospheroid-only liver prints within two weeks of transplantation. Collectively, the proposed platform enables the manufacture of bioactive tissues or organs resembling anatomical architecture, and has broad implications for liver function replacement in clinical applications.
Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future
Authors: Yue-E Wu, Yuan-Yuan Zheng, Qiu-Yue Li, Bu-Fan Yao, Jing Cao, Hui-Xin Liu, Guo-Xiang Hao, John van den Anker, Yi Zheng, Wei Zhao
Journal: Advanced Drug Delivery Reviews (2024)
Generalized pustular psoriasis, palmoplantar pustulosis and plaque psoriasis have different survival rates and healthcare needs
Authors: Laura B von Kobyletzki, Åke Svensson
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis have different survival rates and health care needs Get access Laura B von Kobyletzki, Laura B von Kobyletzki Orebro University, Malmö, SwedenDepartment of Occupational and Environmental Dermatology, Lund University Faculty of Medicine, Malmö, Sweden Correspondence: Laura B. von Kobyletzki Email:laura.von_kobyletzki@med.lu.se Search for other works by this author on: Oxford Academic Google Scholar Åke Svensson Åke Svensson Department of Dermatology, Malmö University Hospital, Malmö, Sweden Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae271, https://doi.org/10.1093/bjd/ljae271 Published: 25 June 2024 Article history Received: 17 June 2024 Accepted: 21 June 2024 Published: 25 June 2024
Engineering microvascular networks using a KLF2 reporter to probe flow-dependent endothelial cell function
Authors: Adriana Blazeski, Marie A. Floryan, Yuzhi Zhang, Oscar R. Fajardo Ramírez, Elamaran Meibalan, Jesús Ortiz-Urbina, Emmanouil Angelidakis, Sarah E. Shelton, Roger D. Kamm, Guillermo García-Cardeña
Journal: Biomaterials (2024)
Predicting elevated natriuretic peptide in chest radiography: emerging utilization gap for artificial intelligence
Authors: Eisuke Kagawa, Masaya Kato, Noboru Oda, Eiji Kunita, Michiaki Nagai, Aya Yamane, Shogo Matsui, Yuki Yoshitomi, Hiroto Shimajiri, Tatsuya Hirokawa, Shunsuke Ishida, Genki Kurimoto, Keigo Dote
Journal:  (2024)

Abstract Aims This study assessed an artificial intelligence (AI) model’s performance in predicting elevated brain natriuretic peptide (BNP) levels from chest radiograms and its effect on diagnostic performance among healthcare professionals. Methods and results Patients who underwent chest radiography and BNP testing on the same day were included. Data were sourced from two hospitals: one for model development, and the other for external testing. Two final ensemble models were developed to predict elevated BNP levels of ≥ 200 pg/mL and ≥ 100 pg/mL, respectively. Humans were evaluated to predict elevated BNP levels, followed by the same test, referring to the AI model’s predictions. A total of 8390 images were collected for model creation, and 1713 images, for tests. The AI model achieved an accuracy of 0.855, precision of 0.873, sensitivity of 0.827, specificity of 0.882, f1 score of 0.850, and receiver-operating-characteristics area-under-curve of 0.929. The accuracy of the testing by 35 participants significantly improved from 0.708 ± 0.049 to 0.829 ± 0.069 (P &amp;lt; 0.001) with the AI assistance (an accuracy of 0.920). Without the AI assistance, the accuracy of the veterans in the medical career was higher than that of early-career professionals (0.728 ± 0.051 vs. 0.692 ± 0.042, P = 0.030); however, with the AI assistance, the accuracy of the early-career professionals was rather higher than that of the veterans (0.851 ± 0.074 vs. 0.803 ± 0.054, P = 0.033). Conclusion The AI model can predict elevated BNP levels from chest radiograms and has the potential to improve human performance. The gap in utilizing new tools represents one of the emerging issues.
Left atrial deformation analysis in patients with non-ischemic dilated cardiomyopathy in atrial fibrillation
Authors: Eduard Ródenas-Alesina, Jordi Lozano-Torres, Pablo Eduardo Tobías-Castillo, Clara Badia-Molins, Rosa Vila-Olives, Maria Calvo-Barceló, Guillem Casas, Toni Soriano-Colomé, Aleix Olivella San Emeterio, Rubén Fernández-Galera, Ana B Méndez-Fernández, José A Barrabés, Ignacio Ferreira-González, José Rodríguez-Palomares
Journal:  (2024)

Atrial fibrillation (AF) is a common comorbidity in non-ischaemic dilated cardiomyopathy (NIDCM) affecting conventional measures of left atrial (LA) function. We aimed to determine whether LA function analysis could identify patients at higher risk of major cardiovascular events (MACEs).
TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance
Authors: Allan M. Johansen, Steven D. Forsythe, Callum Thomas. McGrath, Grayson Barker, Hugo Jimenez, Ravi K. Paluri, Boris C. Pasche
Journal: Clinical Cancer Research (2024)

TGFβ is a pleiotropic signaling pathway that plays a pivotal role in regulating a multitude of cellular functions. TGFβ has a dual role in cell regulation where it induces growth inhibition and cell death; however, it can switch to a growth-promoting state under cancerous conditions. TGFβ is upregulated in colorectal cancer and pancreatic cancer, altering the tumor microenvironment and immune system and promoting a mesenchymal state. The upregulation of TGFβ in certain cancers leads to resistance to immunotherapy, and attempts to inhibit TGFβ expression have led to reduced therapeutic resistance when combined with chemotherapy and immunotherapy. Here, we review the current TGFβ inhibitor drugs in clinical trials for pancreatic and colorectal cancer, with the goal of uncovering advances in improving clinical efficacy for TGFβ combinational treatments in patients. Furthermore, we discuss the relevance of alterations in TGFβ signaling and germline variants in the context of personalizing treatment for patients who show lack of response to current therapeutics.
Traumatic Cervical Spinal Cord Injury and Income and Employment Status
Authors: Rachael H. Jaffe, Peter C. Coyte, Brian C.-F. Chan, Rebecca L. Hancock-Howard, Armaan K. Malhotra, Karim Ladha, Jefferson R. Wilson, Christopher D. Witiw
Journal: JAMA Network Open (2024)

Spinal cord injury (SCI) causes drastic changes to an individual's physical health that may be associated with the ability to work.